Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24329491 | 0.86 | PKM (0.59) | MAOBPKML3MBTL1POLBALDH1A1 | |
| SCHEMBL16959737 | 0.86 | MAOB (0.41) | MAOBHSD17B1ALDH1A1LMNAMAPT | |
| SCHEMBL6181668 | 0.84 | PKM (0.52) | MAOBHSD17B1PKML3MBTL1POLB | |
| SCHEMBL4124943 | 0.84 | EPHX2 (0.55) | L3MBTL1POLBALDH1A1LMNAMAPT | |
| SCHEMBL31387892 | 0.83 | MAOB (0.48) | MAOBPKML3MBTL1POLBALDH1A1 | |
| SCHEMBL22491940 | 0.83 | MAOB (0.48) | MAOBPKML3MBTL1POLBALDH1A1 | |
| SCHEMBL25914488 | 0.82 | PARP1 (0.46) | MAOBCES2CES1 | |
| SCHEMBL1696329 | 0.82 | PARP1 (0.46) | MAOBCES2CES1 | |
| SCHEMBL20218906 | 0.82 | MAOB (0.40) | MAOBHSD17B1MAPTCES2CES1 | |
| SCHEMBL4123049 | 0.82 | CES2 (0.41) | MAOBALDH1A1LMNAMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802127-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | PFIZER INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11691973-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | PFIZER INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20180148453-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-31 | — | — | US | disclosed |
| EP-1507530-B1 | DIAMINOTHIAZOLES AND USE THEREOF AS CDK4 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-11-02 | — | — | EP | disclosed |
| EP-1507530-A1 | DIAMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-23 | — | — | EP | disclosed |
| US-6818663-B2 | AS INHIBITORS OF CYCLIN-DEPENDENT KINASE 4 (CDK4); ANTIPROLIFERATIVE AGENTS; FOR THERAPY OF CANCER, TUMORS | HOFFMANN-LA ROCHES | 2004-11-16 | — | — | US | disclosed |
| US-20040006058-A1 | DIAMINOTHIAZOLES | CHU XIN-JIE (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2003097048-A1 | DIAMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691973-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | NRAS, KRAS, MAPK1 | MAOB 2638/4885HSD17B1 719/4885PKM 1584/4885 |
| US-20180148453-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE4D | MAOB 99/4885HSD17B1 194/4885PKM 492/4885 |
| US-20040006058-A1 | DIAMINOTHIAZOLES | CDK4, CDK1, CDK2 | MAOB 2219/4885HSD17B1 679/4885PKM 355/4885 |
| US-11802127-B2 | 3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors | NRAS, KRAS, MAPK1 | MAOB 2638/4885HSD17B1 719/4885PKM 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.